Nuvalent is creating precisely targeted therapies for patients with cancer designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in structure-based design, Nuvalent develops innovative small molecules with exquisite target selectivity to overcome resistance, minimize adverse events, and drive more durable responses. Nuvalent is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive NSCLC, along with multiple discovery-stage research programs. To learn more, visit www.nuvalent.com.
Location: United States, Massachusetts, Cambridge
Employees: 11-50
Total raised: $187.23M
Founded date: 2017
Investors 3
| Date | Name | Website |
| 17.08.2021 | Logos Capi... | logoscapit... |
| - | Avoro Capi... | avorocapit... |
| - | Bain Capit... | baincapita... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 11.05.2021 | Series B | $135M | - |
| 28.01.2021 | Series A | $52.23M | - |
Mentions in press and media 9
| Date | Title | Description | Source |
| 14.03.2023 | Nuvalent to Present New Preclinical Data on ALK-Selective In... | CAMBRIDGE, Mass., March 14, 2023 /PRNewswire/ -- Nuvalent, Inc. NUVL, a clinical-stage biopharmaceut... | einpresswi... |
| 08.09.2021 | Nuvalent Announces Business and Program Highlights and Repor... | CAMBRIDGE, Mass., Sept. 8, 2021 /PRNewswire/ -- Nuvalent, Inc., (Nasdaq: NUVL), a biopharmaceutica... | prnewswire... |
| 16.05.2021 | Biotech Company Nuvalent Raises $135 Million | Nuvalent — a biotechnology company creating precisely targeted therapies for clinically proven kinas... | pulse2.com... |
| 11.05.2021 | Nuvalent Closes $135M Series B Financing | Nuvalent, Inc., a Cambridge, Mass.-based biotechnology company creating precisely targeted therapies... | finsmes.co... |
| 10.04.2021 | Nuvalent Presents Preclinical Data Demonstrating That ROS1 I... | CAMBRIDGE, Mass., April 10, 2021 /PRNewswire/ -- Nuvalent, Inc., a biotechnology company creating ... | prnewswire... |
| 28.01.2021 | Nuvalent Raises $50M in Series A Financing | Nuvalent, Inc., a Cambridge, MA-based biotechnology company creating precisely targeted therapies fo... | finsmes.co... |
| 27.01.2021 | Nuvalent Raises $50M in Series A | Nuvalent, Inc., a biotechnology company creating precisely targeted therapies for clinically proven ... | citybizlis... |
| 27.01.2021 | Nuvalent, Inc. announced that it has received $52.23494 mill... | Nuvalent, Inc. announced that it has issued 117,457,112 series A preferred stock at a price of $0.44... | marketscre... |
| 27.01.2021 | Nuvalent Launches with $50M Series A Financing from Deerfiel... | CAMBRIDGE, Mass., Jan. 27, 2021 /PRNewswire/ -- Nuvalent, Inc., a biotechnology company creating p... | prnewswire... |